Gilead's 4-drug combo shows early promise against hepatitis C

03/8/2011 | Bloomberg

A four-drug combination from Gilead Sciences showed promise during an early-stage trial in eliminating hepatitis C virus, RBC Capital Markets analysts said. The result supports an ongoing Phase II trial of the drug, which consists of Gilead's compounds GS-9256 and GS-9190 plus standard treatments ribavirin and pegylated interferon.

View Full Article in:

Bloomberg

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Clinical Trials Agreements Specialist (209955)
The Henry M. Jackson Foundation for the Advancement of Military Medicine Inc.
Rockville, MD
SAFETY, HEALTH, and ENVIRONMENTAL (SHE) REGIONAL SPECIALIST
Matheson Tri-Gas, Inc.
Newark, CA
Catheter Engineer
ASAHI INTECC, Orange County CA R&D Center
Santa Ana, CA
MANAGER MEDICAL GAS COMPLIANCE AND SAFETY
Matheson Tri-Gas, Inc.
Houston, TX
Neurovascular Intervention Product Sales Rep, North East
ASAHI INTECC
Multiple Locations, SL_Multiple Locations